Authors: Mamdooh Ghoneum Nariman K Badr ElDin Eman Noaman Lucilene Tolentino
Publish Date: 2007/09/22
Volume: 57, Issue: 4, Pages: 581-592
Abstract
This study was undertaken to evaluate the effectiveness and mechanisms of antitumor activity of Baker’s yeast Saccharomyces cerevisiae in immunocompetent mice Swiss albino mice were inoculated intramuscularly in the right thigh with Ehrlich Ascites Carcinoma EAC cells At day 8 mice bearing Solid Ehrlich Carcinoma tumor SEC were intratumorally IT injected with killed S cerevisiae 10 × 106 and 20 × 106 cells for 35 days Histopathology of yeasttreated mice showed extensive tumor degeneration apoptosis and ischemic coagulative and liquefactive necrosis These changes are associated with a tumor growth curve that demonstrates a significant antitumor response that peaked at 35 days Yeast treatment 20 × 106 cells three times a week resulted in a significant decrease in tumor volume TV 671 P 001 as compared to PBStreated mice The effect was determined to be dependent on dose and frequency Yeast administered three and two times per week induced significant decrease in TV as early as 9 and 25 days posttreatment respectively Administration of yeast significantly enhanced the recruitment of leukocytes including macrophages into the tumors and triggered apoptosis in SEC cells as determined by flow cytometry 786 P 001 at 20 × 106 cells as compared to PBStreated mice 426 In addition yeast treatment elevated TNFα and IFNγ plasma levels and lowered the elevated IL10 levels No adverse side effects from the yeast treatment were observed including feeding/drinking cycle and life activity patterns Indeed yeasttreated mice showed significant final body weight gain +215 P 001 at day 35 These data may have clinical implications for the treatment of solid cancer with yeast which is known to be safe for human consumption
Keywords: